Edition:
United Kingdom

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

15.00USD
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
$15.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
385,820
52-wk High
$19.94
52-wk Low
$13.44

Latest Key Developments (Source: Significant Developments)

Sun Pharmaceutical Industries Announces Settlement Of Patent Litigation For Generic Linzess In U.S.
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO'S UNITS HAVE REACHED AN AGREEMENT WITH IRONWOOD PHARMACEUTICALS, INC. AND ALLERGAN PLC.ANNOUNCES SETTLEMENT OF PATENT LITIGATION FOR GENERIC LINZES IN US.COMPANIES TO GRANT CO'S UNITS LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S FROM FEB 1, 2031 OR EARLIER UNDER CIRCUMSTANCES.ADDITIONAL DETAILS REGARDING THE SETTLEMENT WERE NOT DISCLOSED..  Full Article

Allergan, Ironwood Announce Settlement With Sun Pharma
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.  Full Article

Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017.IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​.IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017.IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017.  Full Article

Ironwood Pharmaceuticals Strengthens Executive Leadership Team
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM.IRONWOOD PHARMACEUTICALS INC - PROMOTED ‍ GINA CONSYLMAN TO SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.  Full Article

Ironwood Pharma files for potential mixed shelf offering
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​.  Full Article

Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Q3 non-GAAP loss per share $0.18.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Ironwood Pharmaceuticals provides third quarter 2017 investor update.Q3 loss per share $0.22.Q3 revenue $87 million versus I/B/E/S view $73.6 million.Ironwood Pharmaceuticals Inc sees 2017 ‍R&D expenses to be in low-to-middle end of previously guided $145 million to $160 million range​.Ironwood Pharmaceuticals Inc - ‍data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017​.Ironwood Pharmaceuticals Inc - ‍to use less than $110 million in cash for operations in 2017, up from less than $100 million previously guided​.Ironwood - sees co & Allergan's ‍combined total 2017 marketing & sales expenses for Linzess in middle of previously guided $250 million to $280 million range​.Ironwood Pharmaceuticals Inc - co & Allergan no longer intend to pursue linaclotide delayed release-1​.  Full Article

Ironwood Pharma Q2 adj shr loss $0.16
Thursday, 4 Aug 2016 

Ironwood Pharmaceuticals Inc : Ironwood pharmaceuticals provides second quarter 2016 investor update . Q2 gaap loss per share $0.15 . Q2 revenue $54.4 million versus i/b/e/s view $55.5 million . Q2 non-gaap loss per share $0.16 . Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S . Allergan and ironwood continue to expect total 2016 marketing and sales expenses for linzess to be in range of $230 million to $260 million . Says continues to expect to use less than $70 million in cash for operations in 2016 . Q2 earnings per share view $-0.15, revenue view $55.5 million -- Thomson Reuters I/B/E/S Further company coverage: [IRWD.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Allergan says supplemental NDA for 72 mcg Linaclotide accepted for FDA review
Thursday, 9 Jun 2016 

Allergan Plc : FDA prescription drug user fee act (PDUFA) target action date is expected to occur in early 2017 . FDA accepted for review SNDA for 72 mcg dose of Linaclotide for use in treatment of adults with chronic idiopathic constipation .Ironwood and Allergan announce supplemental new drug application for 72 mcg Linaclotide in chronic idiopathic constipation has been accepted for FDA review.  Full Article

Ironwood Pharmaceuticals Q1 gaap loss per share $0.09
Monday, 9 May 2016 

Ironwood Pharmaceuticals Inc : Ironwood on track to achieve positive cash flow in 2018 . Ironwood pharmaceuticals provides first quarter 2016 investor update . Q1 non-gaap loss per share $0.08 . Q1 gaap loss per share $0.09 . Q1 revenue $66 million versus i/b/e/s view $53.6 million .Q1 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION